Literature DB >> 20200641

Vanishing platelets: rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction.

Nasir Rahman1, Fahim H Jafary.   

Abstract

Glycoprotein IIb/IIIa inhibitors are established treatment for patients who develop acute coronary syndromes. Thrombocytopenia is known to occur following the administration of various drugs, including heparin and glycoprotein IIb/IIIa inhibitors. In the case of glycoprotein IIb/IIIa inhibitors, the mechanism is thought to be drug-dependent antibodies. In most cases, the thrombocytopenia is mild or moderate in severity. Severe thrombocytopenia (platelet count, <50 x 10(9)/L) is distinctly rare. Herein, we report a case of tirofiban-induced thrombocytopenia in which the overall platelet count dropped precipitously to <1 x 10(9)/L within 12 hours of administration; recovery was relatively prolonged, possibly owing to concomitant renal insufficiency. The severity and the rapidity of onset emphasize the need to routinely check platelet counts early after tirofiban administration, in order to prevent sequelae.

Entities:  

Keywords:  Acute coronary syndromes; glycoprotein IIb/IIIa inhibitors; percutaneous coronary intervention; thrombocytopenia; tirofiban

Mesh:

Substances:

Year:  2010        PMID: 20200641      PMCID: PMC2829794     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  17 in total

Review 1.  Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors.

Authors:  M Madan; S D Berkowitz
Journal:  Am Heart J       Date:  1999-10       Impact factor: 4.749

2.  A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.

Authors: 
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

3.  Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

4.  Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated.

Authors:  Jeffrey T Billheimer; Ira B Dicker; Richard Wynn; Jodi D Bradley; Debra A Cromley; Helen E Godonis; Lisa C Grimminger; Bokang He; Cathy J Kieras; Donna L Pedicord; Susan M Spitz; Beth E Thomas; Nina I Zolotarjova; Mary A Gorko; Gregory F Hollis; Robert N Daly; Andrew M Stern; Dietmar Seiffert
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

5.  Abciximab readministration: results of the ReoPro Readministration Registry.

Authors:  J E Tcheng; D J Kereiakes; A M Lincoff; B S George; N S Kleiman; D C Sane; D B Cines; R E Jordan; M A Mascelli; M A Langrall; L Damaraju; A Schantz; M B Effron; G A Braden
Journal:  Circulation       Date:  2001-08-21       Impact factor: 29.690

6.  Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.

Authors:  Daniel W Bougie; Peter R Wilker; Elizabeth D Wuitschick; Brian R Curtis; Mohammad Malik; Stewart Levine; Richard N Lind; Jaime Pereira; Richard H Aster
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

7.  Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.

Authors:  Piera Angelica Merlini; Marco Rossi; Alberto Menozzi; Silvia Buratti; Danielle M Brennan; David J Moliterno; Eric J Topol; Diego Ardissino
Journal:  Circulation       Date:  2004-04-26       Impact factor: 29.690

Review 8.  Heparin induced thrombocytopenia: pathogenetic, clinical, diagnostic and therapeutic aspects.

Authors:  R Castelli; E Cassinerio; M D Cappellini; F Porro; G Graziadei; F Fabris
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2007-09

9.  Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment.

Authors:  D L Brown
Journal:  Heart       Date:  2003-05       Impact factor: 5.994

10.  Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.

Authors:  C M Gibson; M Goel; D J Cohen; R N Piana; L I Deckelbaum; K E Harris; S B King
Journal:  J Am Coll Cardiol       Date:  1998-07       Impact factor: 24.094

View more
  5 in total

Review 1.  Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review.

Authors:  Omer Celal Elcioglu; Abdullah Ozkok; Timur Selcuk Akpınar; Fatih Tufan; Murat Sezer; Sabahattin Umman; Sevgi Kalayoglu Besısık
Journal:  Int J Hematol       Date:  2012-07-06       Impact factor: 2.490

2.  Acute serious thrombocytopenia associated with intracoronary tirofiban use for primary angioplasty.

Authors:  Mustafa Yurtdaş; Yalin Tolga Yaylali; Nesim Aladağ; Mahmut Ozdemir; Memiş Hilmi Atay
Journal:  Case Rep Med       Date:  2014-03-10

3.  A Case of Hyperacute Severe Thrombocytopenia Occurring Less than 24 Hours after Intravenous Tirofiban Infusion.

Authors:  Vineet Meghrajani; Nitin Sabharwal; Vinod Namana; Moustafa Elsheshtawy; Bernard Topi
Journal:  Case Rep Hematol       Date:  2018-05-24

4.  Tirofiban Induced Thrombocytopenia: A Rare but Severe Adverse Effect.

Authors:  Muhammad Shabbir Rawala; Amna Saleem Ahmed; Kanna Posina; Varun Sundaram
Journal:  J Community Hosp Intern Med Perspect       Date:  2020-05-21

5.  An Unusual Case of Drug-Induced Thrombocytopenia.

Authors:  Shiyu Wang; Khalid Sawalha; Atif Khan
Journal:  J Investig Med High Impact Case Rep       Date:  2020 Jan-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.